The nasal transcriptome reflects clinically relevant disease activity in NOVELTY, with a different signal in asthma and in COPD

van den Berge,M.,Hylkema,M. N.,Nawijn,M. C.,Wen,H.,Janson,C.,Azim,A.,Jayaraman,A.,Lui,Z.,Anderson,G.,De Baets,G.,Hughes,R.,Müllerova,H.,Muthas,D.,Öberg,L.,Ostridge,K.,Platt,A.,Scott,I. C.,Faner,R.,Christenson,S. A.,For The Novelty Scientific Community And The Novelty Study Investigators,-
DOI: https://doi.org/10.1183/13993003.congress-2024.pa4389
IF: 24.3
2024-11-01
European Respiratory Journal
Abstract:Background: Nasal airway sampling is a promising, easily accessible avenue to identify lower airway biology for endotyping, per the 'united airways' hypothesis. We aimed to assess associations of a 9-gene score, upregulated in both bronchial and upper airways in asthma, with clinical disease in patients with asthma and COPD from a sub-study of NOVELTY (NCT02760329). Methods: Nasal brushes were collected in 122 and 86 patients with physician-assigned asthma and COPD, respectively, and profiled using RNAseq. A composite 9-gene score was generated via Gene Set Variation Analysis. Group differences were assessed, adjusting for sex, age and season. Results: In asthma, higher gene scores were associated with greater airflow obstruction and type 2 inflammatory biomarkers, but not physician-assessed severity, inhaled corticosteroid (ICS) use or exacerbations (Figure A). In COPD, higher gene scores were associated with lower physician-assessed severity, less airflow obstruction, fewer exacerbations, less ICS use and elevated fractional exhaled nitric oxide, but not blood eosinophils (Figure B). Conclusion: Our findings indicate that nasal gene expression profiling has potential as a tool for airway disease biomarker development, providing insight into distinct biological patterns in asthma and in COPD.
respiratory system
What problem does this paper attempt to address?